^
    1d
    Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC (clinicaltrials.gov)
    P2, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    1d
    Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=474, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    1d
    A Phase 1 Study of IM-1617 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=175, Not yet recruiting, Immunome, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1)
    |
    HER-2 negative • RAS wild-type
    1d
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)
    1d
    Photon Intensity-modulated Radiotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P=N/A, N=504, Not yet recruiting, Guangzhou Concord Cancer Center
    New trial
    1d
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=148, Recruiting, Sun Yat-sen University | Trial completion date: Jul 2028 --> Dec 2028 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Loqtorzi (toripalimab-tpzi)
    1d
    Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition (clinicaltrials.gov)
    P3, N=266, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2024 --> Dec 2029 | Trial primary completion date: Jul 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin
    1d
    Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    cisplatin
    1d
    EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=148, Recruiting, Sun Yat-sen University | Trial completion date: Feb 2029 --> Jun 2029 | Trial primary completion date: Feb 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine
    1d
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial (clinicaltrials.gov)
    P3, N=212, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Loqtorzi (toripalimab-tpzi)
    1d
    Vocal folds irregular mucosal changes: a multimodal evaluation for diagnosis and genetic risk stratification. (PubMed, Eur Arch Otorhinolaryngol)
    This study integrated established diagnostic standards, laryngostroboscopy for clinical assessment, and histopathology as the gold standard for grading, while the analysis of SOX2 gene expression showed a promising predictive molecular marker for tumorigenesis.
    Journal
    |
    SOX2
    |
    Akeega (abiraterone/niraparib)
    1d
    MMP1 and PRSS23 induce PAR2 biased agonism in painful oral cancers. (PubMed, Commun Biol)
    We propose that PAR2 activation in oral N+ cancers from patients with pain is driven by high levels of MMP1 and PRSS23. Our study informs design of signaling and location-specific antagonists to provide more efficacious analgesia.
    Journal
    |
    CTSS (Cathepsin S) • MMP1 (Matrix metallopeptidase 1) • ST14 (ST14 transmembrane serine protease matriptase) • PRSS23 (Serine Protease 23)